董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Lorin K. Johnson | 男 | Director | 68 | 14.12万美元 | 未持股 | 2021-05-12 |
| Michael Rice | 男 | Director | 56 | 未披露 | 未持股 | 2021-05-12 |
| Mark Sirgo | 男 | Director | 67 | 22.42万美元 | 未持股 | 2021-05-12 |
| Michael Constantino | 男 | Director | 58 | 10.03万美元 | 未持股 | 2021-05-12 |
| John Temperato | 男 | Director,Chief Executive Officer | 56 | 206.82万美元 | 未持股 | 2021-05-12 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Edward J. Sitar | 男 | Chief Financial Officer | 60 | 77.92万美元 | 未持股 | 2021-05-12 |
| John Temperato | 男 | Director,Chief Executive Officer | 56 | 206.82万美元 | 未持股 | 2021-05-12 |
董事简历
中英对照 | 中文 | 英文- Lorin K. Johnson
-
LorinK.Johnson于2018年1月加入董事会。他是Glycyx PharmaVentures Ltd.（生物制药投资和开发公司）的创始人兼首席科学家。他于1989年共同创立Salix Pharmaceuticals公司（纳斯达克上市的专业制药公司），并于2015年4月被Valeant Pharmaceuticals International公司以158亿美元收购之前担任高级领导职务。在加入Salix之前，Johnson博士担任Scios，Inc.（前身为California Biotechnology，Inc.）的科学运营总监兼首席科学家。他是Glycyx Mor，Ltd和Kinisi Therapeutics，Ltd.的董事会成员，这两家公司都是基于马恩岛完整公司（位于加利福尼亚州贝尔蒙特的GI专业药物输送公司）和肿瘤追踪有限公司（位于英国诺丁汉的癌症诊断公司）的GI专业制药公司。除了他的工业职业生涯，Johnson博士曾担任斯坦福大学医学中心（Stanford University Medical Center）病理学助理教授，并在斯坦福大学医学院（Stanford University School of Medicine）和旧金山加利福尼亚大学（University of California，San Francisco）担任学术职位。他是75篇期刊文章和书籍章节的共同作者，也是22项已发布专利的共同发明人。Johnson博士拥有南加州大学（University of Southern California）的博士学位，曾是加州大学旧金山分校（University of California，San Francisco）的博士后。
Lorin K. Johnson joined our Board in January 2018. He is the founder and Chief Scientist of Glycyx PharmaVentures Ltd., a biopharma investment and development company. In 1989 he co-founded Salix Pharmaceuticals, Inc. Nasdaq: SLXP, a specialty pharmaceutical company specializing in gastrointestinal products, and held senior leadership positions prior to its $15.8 billion acquisition by Valeant Pharmaceuticals International, Inc. (NYSEA: VRX) in April 2015. Prior to Salix, Dr. Johnson served as Director of Scientific Operations and Chief Scientist at Scios, Inc. (formerly California Biotechnology, Inc). Since June 2019 he has been a board member of Edesa Biotech, Inc. (Nasdaq: EDSA), a biopharmaceutical company in the fields of inflammation, infectious disease and gastroenterology. He is also a board member of Glycyx MOR, LTD and Kinisi Therapeutics, Ltd., both GI specialty pharma companies based on the Isle of Man, as well as Intact Inc., a GI specialty drug delivery company based in Belmont, CA. In addition to his career in industry, Dr. Johnson has served as an Assistant Professor of Pathology at Stanford University Medical Center and held academic positions at Stanford University School of Medicine and the University of California, San Francisco. He is the co-author of 75 journal articles and book chapters and is the co-inventor on 22 issued patents. Dr. Johnson holds a Ph.D. from the University of Southern California and was a Postdoctoral Fellow at the University of California, San Francisco. - LorinK.Johnson于2018年1月加入董事会。他是Glycyx PharmaVentures Ltd.（生物制药投资和开发公司）的创始人兼首席科学家。他于1989年共同创立Salix Pharmaceuticals公司（纳斯达克上市的专业制药公司），并于2015年4月被Valeant Pharmaceuticals International公司以158亿美元收购之前担任高级领导职务。在加入Salix之前，Johnson博士担任Scios，Inc.（前身为California Biotechnology，Inc.）的科学运营总监兼首席科学家。他是Glycyx Mor，Ltd和Kinisi Therapeutics，Ltd.的董事会成员，这两家公司都是基于马恩岛完整公司（位于加利福尼亚州贝尔蒙特的GI专业药物输送公司）和肿瘤追踪有限公司（位于英国诺丁汉的癌症诊断公司）的GI专业制药公司。除了他的工业职业生涯，Johnson博士曾担任斯坦福大学医学中心（Stanford University Medical Center）病理学助理教授，并在斯坦福大学医学院（Stanford University School of Medicine）和旧金山加利福尼亚大学（University of California，San Francisco）担任学术职位。他是75篇期刊文章和书籍章节的共同作者，也是22项已发布专利的共同发明人。Johnson博士拥有南加州大学（University of Southern California）的博士学位，曾是加州大学旧金山分校（University of California，San Francisco）的博士后。
- Lorin K. Johnson joined our Board in January 2018. He is the founder and Chief Scientist of Glycyx PharmaVentures Ltd., a biopharma investment and development company. In 1989 he co-founded Salix Pharmaceuticals, Inc. Nasdaq: SLXP, a specialty pharmaceutical company specializing in gastrointestinal products, and held senior leadership positions prior to its $15.8 billion acquisition by Valeant Pharmaceuticals International, Inc. (NYSEA: VRX) in April 2015. Prior to Salix, Dr. Johnson served as Director of Scientific Operations and Chief Scientist at Scios, Inc. (formerly California Biotechnology, Inc). Since June 2019 he has been a board member of Edesa Biotech, Inc. (Nasdaq: EDSA), a biopharmaceutical company in the fields of inflammation, infectious disease and gastroenterology. He is also a board member of Glycyx MOR, LTD and Kinisi Therapeutics, Ltd., both GI specialty pharma companies based on the Isle of Man, as well as Intact Inc., a GI specialty drug delivery company based in Belmont, CA. In addition to his career in industry, Dr. Johnson has served as an Assistant Professor of Pathology at Stanford University Medical Center and held academic positions at Stanford University School of Medicine and the University of California, San Francisco. He is the co-author of 75 journal articles and book chapters and is the co-inventor on 22 issued patents. Dr. Johnson holds a Ph.D. from the University of Southern California and was a Postdoctoral Fellow at the University of California, San Francisco.
- Michael Rice
-
自2019年6月以来，Michael Rice为我们的首席运营官兼董事会成员。在2010年3月共同创立LifeSci Advisors和LifeSci Capital之前，Michael从2007年4月到2008年11月担任Canaccord Adams医疗保健投资银行业务联席主管，参与债务和股权融资。Michael从2005年4月到2007年4月担任ThinkEquity Partners总经理，负责管理Healthcare Capital市场，包括构建和执行许多交易，其中许多是ThinkEquity的第一次交易。在此之前，Michael从2003年8月到2005年3月担任Banc of America总经理，为大型对冲基金和私人股本梦百合基金服务。此前，他曾担任JPMorgan/Hambrecht&Quist的董事总经理。Michael自2016年1月起担任RDD Pharma Ltd.董事，自2016年5月起担任Navidea Biopharmaceuticals Inc.董事。Michael自2019年6月起担任特殊目的收购公司LifeSci Acquisition Corp.的首席运营官和董事。Michael在University of Maryland获得文学学士学位。迈克尔拥有72463系列和79系列的许可证。
Michael Rice, has been Chief Operating Officer and Board member since December 2019 and has experience in portfolio management, corporate management, investment banking and capital markets. Prior to co-founding LifeSci Advisors and LifeSci Capital, Michael was the co-head of healthcare investment banking at Canaccord Adams, where he was involved in debt and equity financing. Michael was also Managing Director at ThinkEquity Partners where he was responsible for managing Healthcare Capital Markets, which included structuring and executing numerous transactions, many of which were firsts at ThinkEquity. Prior to that, Michael served as a Managing Director at Banc of America, serving large hedge funds and private equity healthcare funds. Michael was the Chief Operating Officer and a director of LifeSci Acquisition Corp., a special purpose acquisition company, from June 2019 until its merger with Vincerx Pharma Inc. in December 2020. Previously, he was a Managing Director at JPMorgan/Hambrecht & Quist. - 自2019年6月以来，Michael Rice为我们的首席运营官兼董事会成员。在2010年3月共同创立LifeSci Advisors和LifeSci Capital之前，Michael从2007年4月到2008年11月担任Canaccord Adams医疗保健投资银行业务联席主管，参与债务和股权融资。Michael从2005年4月到2007年4月担任ThinkEquity Partners总经理，负责管理Healthcare Capital市场，包括构建和执行许多交易，其中许多是ThinkEquity的第一次交易。在此之前，Michael从2003年8月到2005年3月担任Banc of America总经理，为大型对冲基金和私人股本梦百合基金服务。此前，他曾担任JPMorgan/Hambrecht&Quist的董事总经理。Michael自2016年1月起担任RDD Pharma Ltd.董事，自2016年5月起担任Navidea Biopharmaceuticals Inc.董事。Michael自2019年6月起担任特殊目的收购公司LifeSci Acquisition Corp.的首席运营官和董事。Michael在University of Maryland获得文学学士学位。迈克尔拥有72463系列和79系列的许可证。
- Michael Rice, has been Chief Operating Officer and Board member since December 2019 and has experience in portfolio management, corporate management, investment banking and capital markets. Prior to co-founding LifeSci Advisors and LifeSci Capital, Michael was the co-head of healthcare investment banking at Canaccord Adams, where he was involved in debt and equity financing. Michael was also Managing Director at ThinkEquity Partners where he was responsible for managing Healthcare Capital Markets, which included structuring and executing numerous transactions, many of which were firsts at ThinkEquity. Prior to that, Michael served as a Managing Director at Banc of America, serving large hedge funds and private equity healthcare funds. Michael was the Chief Operating Officer and a director of LifeSci Acquisition Corp., a special purpose acquisition company, from June 2019 until its merger with Vincerx Pharma Inc. in December 2020. Previously, he was a Managing Director at JPMorgan/Hambrecht & Quist.
- Mark Sirgo
-
Mark Sirgo在RDD合并完成后于2020年4月加入我们的董事会，并被任命为董事会主席。2019年1月，Sirgo博士被任命为私人中枢神经系统和神经退行性疾病开发公司Aruna Bio的首席执行官。Sirgo博士担任BioDelivery Sciences International, Inc.的董事NASDAQ:BDSI，2005年8月以来，他一直担任该职位。自2016年10月起，他还担任BDSI董事会副主席。他于2005年1月至2018年1月担任BDSI总裁，并于2005年8月至2018年1月担任首席执行官。他于2004年8月加入BDSI，担任商业化和企业发展的高级副总裁，该公司收购了Arius Pharmaceuticals，他是该公司的联合创始人兼首席执行官。他还曾担任BDSI’；的执行副总裁，负责公司和商业开发，以及首席运营官。Sirgo博士在制药行业拥有超过30年的经验，包括16年的临床药物开发经验，7年的市场营销、销售和业务开发经验，以及12年的执行管理职位。在加入Arius Pharmaceuticals之前，从2003年到2004年，他在Glaxo，Glaxo Wellcome和GlaxoSmithKline的临床开发和营销方面担任了16年的各种职位，职责不断增加，包括国际OTC开发的副总裁和新产品营销的副总裁。在Glaxo Wellcome任职期间，Sirgo博士负责管理Zantac75的开发和FDA批准，以及其他成就。从1996年到1999年，Sirgo博士担任Pharmaceutical Product Development, Inc.（一家制药行业的领先合同服务提供商）的全球销售与市场营销高级副总裁。从2008年到2015年出售，Sirgo博士担任Salix Pharmaceuticals，Inc.（纳斯达克代码:SLXP）的董事会成员和薪酬委员会主席，这是一家专业制药公司，专注于胃肠道产品。Sirgo博士于2016年7月加入诊断和治疗公司Biomerica, Inc.（纳斯达克代码:BMRA）的董事会，并于2018年4月至RDD合并期间担任RDD Pharma的董事会主席。Sirgo博士在俄亥俄州立大学获得药剂学学士学位，并在费城药学院获得博士学位。
Mark Sirgo joined our Board in April 2020 upon completion of the RDD Merger and was appointed as Board chairman. In January 2019 Dr. Sirgo was appointed Chief Executive Officer of ArunA Bio, a private central nervous system and neurodegenerative disorder development company. Dr. Sirgo serves as a director of BioDelivery Sciences International, Inc. Nasdaq: BDSI, a position he has held since August 2005. He also has served as the Vice Chairman of the BDSI board since October 2016. He was President of BDSI from January 2005 to January 2018 and Chief Executive Officer from August 2005 to January 2018. He joined BDSI in August 2004 as Senior Vice President of Commercialization and Corporate Development upon its acquisition of Arius Pharmaceuticals, of which he was a co-founder and Chief Executive Officer. He also previously served as BDSI’s Executive Vice President, Corporate and Commercial Development and its Chief Operating Officer. Dr. Sirgo has over 30 years of experience in the pharmaceutical industry, including 16 years in clinical drug development, 7 years in marketing, sales, and business development, and 12 years in executive management positions. Prior to his involvement with Arius Pharmaceuticals, from 2003 to 2004 he spent 16 years in a variety of positions of increasing responsibility in both clinical development and marketing at Glaxo, Glaxo Wellcome, and GlaxoSmithKline, including Vice President of International OTC Development and Vice President of New Product Marketing. Dr. Sirgo was responsible for managing the development and FDA approval of Zantac 75 while at Glaxo Wellcome, among other accomplishments. From 1996 to 1999 Dr. Sirgo was Senior Vice President of Global Sales and Marketing at Pharmaceutical Product Development, Inc., a leading contract service provider to the pharmaceutical industry. Dr. Sirgo served on the Board of Directors and as Chairman of the Compensation Committee of Salix Pharmaceuticals, Inc. (Nasdaq: SLXP), a specialty pharmaceutical company specializing in gastrointestinal products, from 2008 until its sale in 2015. Dr. Sirgo was added to the Board of Directors of Biomerica, Inc. (Nasdaq: BMRA), a diagnostics and therapeutic company, in July 2016 and served as Chairman of the Board of RDD Pharma from April 2018 until the RDD Merger. Dr. Sirgo received his BS in Pharmacy from The Ohio State University and his Doctorate from Philadelphia College of Pharmacy and Science. - Mark Sirgo在RDD合并完成后于2020年4月加入我们的董事会，并被任命为董事会主席。2019年1月，Sirgo博士被任命为私人中枢神经系统和神经退行性疾病开发公司Aruna Bio的首席执行官。Sirgo博士担任BioDelivery Sciences International, Inc.的董事NASDAQ:BDSI，2005年8月以来，他一直担任该职位。自2016年10月起，他还担任BDSI董事会副主席。他于2005年1月至2018年1月担任BDSI总裁，并于2005年8月至2018年1月担任首席执行官。他于2004年8月加入BDSI，担任商业化和企业发展的高级副总裁，该公司收购了Arius Pharmaceuticals，他是该公司的联合创始人兼首席执行官。他还曾担任BDSI’；的执行副总裁，负责公司和商业开发，以及首席运营官。Sirgo博士在制药行业拥有超过30年的经验，包括16年的临床药物开发经验，7年的市场营销、销售和业务开发经验，以及12年的执行管理职位。在加入Arius Pharmaceuticals之前，从2003年到2004年，他在Glaxo，Glaxo Wellcome和GlaxoSmithKline的临床开发和营销方面担任了16年的各种职位，职责不断增加，包括国际OTC开发的副总裁和新产品营销的副总裁。在Glaxo Wellcome任职期间，Sirgo博士负责管理Zantac75的开发和FDA批准，以及其他成就。从1996年到1999年，Sirgo博士担任Pharmaceutical Product Development, Inc.（一家制药行业的领先合同服务提供商）的全球销售与市场营销高级副总裁。从2008年到2015年出售，Sirgo博士担任Salix Pharmaceuticals，Inc.（纳斯达克代码:SLXP）的董事会成员和薪酬委员会主席，这是一家专业制药公司，专注于胃肠道产品。Sirgo博士于2016年7月加入诊断和治疗公司Biomerica, Inc.（纳斯达克代码:BMRA）的董事会，并于2018年4月至RDD合并期间担任RDD Pharma的董事会主席。Sirgo博士在俄亥俄州立大学获得药剂学学士学位，并在费城药学院获得博士学位。
- Mark Sirgo joined our Board in April 2020 upon completion of the RDD Merger and was appointed as Board chairman. In January 2019 Dr. Sirgo was appointed Chief Executive Officer of ArunA Bio, a private central nervous system and neurodegenerative disorder development company. Dr. Sirgo serves as a director of BioDelivery Sciences International, Inc. Nasdaq: BDSI, a position he has held since August 2005. He also has served as the Vice Chairman of the BDSI board since October 2016. He was President of BDSI from January 2005 to January 2018 and Chief Executive Officer from August 2005 to January 2018. He joined BDSI in August 2004 as Senior Vice President of Commercialization and Corporate Development upon its acquisition of Arius Pharmaceuticals, of which he was a co-founder and Chief Executive Officer. He also previously served as BDSI’s Executive Vice President, Corporate and Commercial Development and its Chief Operating Officer. Dr. Sirgo has over 30 years of experience in the pharmaceutical industry, including 16 years in clinical drug development, 7 years in marketing, sales, and business development, and 12 years in executive management positions. Prior to his involvement with Arius Pharmaceuticals, from 2003 to 2004 he spent 16 years in a variety of positions of increasing responsibility in both clinical development and marketing at Glaxo, Glaxo Wellcome, and GlaxoSmithKline, including Vice President of International OTC Development and Vice President of New Product Marketing. Dr. Sirgo was responsible for managing the development and FDA approval of Zantac 75 while at Glaxo Wellcome, among other accomplishments. From 1996 to 1999 Dr. Sirgo was Senior Vice President of Global Sales and Marketing at Pharmaceutical Product Development, Inc., a leading contract service provider to the pharmaceutical industry. Dr. Sirgo served on the Board of Directors and as Chairman of the Compensation Committee of Salix Pharmaceuticals, Inc. (Nasdaq: SLXP), a specialty pharmaceutical company specializing in gastrointestinal products, from 2008 until its sale in 2015. Dr. Sirgo was added to the Board of Directors of Biomerica, Inc. (Nasdaq: BMRA), a diagnostics and therapeutic company, in July 2016 and served as Chairman of the Board of RDD Pharma from April 2018 until the RDD Merger. Dr. Sirgo received his BS in Pharmacy from The Ohio State University and his Doctorate from Philadelphia College of Pharmacy and Science.
- Michael Constantino
-
Michael Constantino于2020年6月加入我们的董事会。Constantino先生是一位退休的Ernst&Young LLP保证合伙人，他在北卡罗来纳州的研究三角公园地区服务了30多年。从2009年到2012年，他担任罗利/格林斯伯勒办公室的管理合伙人，该办公室有200多名员工。他负责领导一个不断增长的业务，包括保险、咨询和税务服务，专注于代表许多行业的上市和私人持有的创业公司。在该公司的职业生涯中，他曾在几家公司工作，包括生命科学公司生物技术，医疗设备和制药，合同研究组织，技术，制造和运输公司，以及大型SEC注册人。Mike协助客户进行了20多次首次公开发行、债务发行、并购交易和私募股权发行。他在从初创企业到成熟的公共实体的整个发展过程中与公司密切合作，并协助管理团队和董事会处理SEC合规事务、Sarbanes-Oxley内部控制、全球运营和战略规划。目前，他是NC State Foundation的董事会主席和Green Chair Project的董事会主席。Mike拥有北卡罗来纳州立大学会计和商业管理学士学位，也是北卡罗来纳州的注册会计师。
Michael Constantino joined our Board in June 2020. Mr. Constantino is a retired Ernst & Young LLP assurance partner who served in the Research Triangle Park Region of North Carolina for over 30 years. From 2009 to 2012 he served as the Office Managing Partner for the combined Raleigh/Greensboro office with over 200 employees. He was responsible for leading a growing practice that included assurance, advisory and tax services focused on public and privately held entrepreneurial companies representing many industries. During his career with the firm, he worked with several companies including life sciences companies biotechnology, medical device and pharmaceuticals, contract research organizations, technology, manufacturing and transportation companies, and large SEC registrants. Mike assisted clients with over 20 initial public offerings, debt offerings, mergers and acquisition transactions, and private equity offerings. He worked closely with companies across the development continuum from start-up to mature public entities and assisted management teams and boards of directors with SEC compliance matters, Sarbanes-Oxley internal controls, global operations and strategic planning. Currently, he is the Chair of the Board for the NC State Foundation and Chair of the Board of The Green Chair Project. Mike holds a B.A. in both Accounting and Business Management from NC State University and is a North Carolina CPA. - Michael Constantino于2020年6月加入我们的董事会。Constantino先生是一位退休的Ernst&Young LLP保证合伙人，他在北卡罗来纳州的研究三角公园地区服务了30多年。从2009年到2012年，他担任罗利/格林斯伯勒办公室的管理合伙人，该办公室有200多名员工。他负责领导一个不断增长的业务，包括保险、咨询和税务服务，专注于代表许多行业的上市和私人持有的创业公司。在该公司的职业生涯中，他曾在几家公司工作，包括生命科学公司生物技术，医疗设备和制药，合同研究组织，技术，制造和运输公司，以及大型SEC注册人。Mike协助客户进行了20多次首次公开发行、债务发行、并购交易和私募股权发行。他在从初创企业到成熟的公共实体的整个发展过程中与公司密切合作，并协助管理团队和董事会处理SEC合规事务、Sarbanes-Oxley内部控制、全球运营和战略规划。目前，他是NC State Foundation的董事会主席和Green Chair Project的董事会主席。Mike拥有北卡罗来纳州立大学会计和商业管理学士学位，也是北卡罗来纳州的注册会计师。
- Michael Constantino joined our Board in June 2020. Mr. Constantino is a retired Ernst & Young LLP assurance partner who served in the Research Triangle Park Region of North Carolina for over 30 years. From 2009 to 2012 he served as the Office Managing Partner for the combined Raleigh/Greensboro office with over 200 employees. He was responsible for leading a growing practice that included assurance, advisory and tax services focused on public and privately held entrepreneurial companies representing many industries. During his career with the firm, he worked with several companies including life sciences companies biotechnology, medical device and pharmaceuticals, contract research organizations, technology, manufacturing and transportation companies, and large SEC registrants. Mike assisted clients with over 20 initial public offerings, debt offerings, mergers and acquisition transactions, and private equity offerings. He worked closely with companies across the development continuum from start-up to mature public entities and assisted management teams and boards of directors with SEC compliance matters, Sarbanes-Oxley internal controls, global operations and strategic planning. Currently, he is the Chair of the Board for the NC State Foundation and Chair of the Board of The Green Chair Project. Mike holds a B.A. in both Accounting and Business Management from NC State University and is a North Carolina CPA.
- John Temperato
-
John Temperato在RDD合并完成后于2020年4月加入我们的董事会，并被任命为我们的首席执行官。Temperato先生从2019年3月至2020年4月担任RDD首席执行官。在加入RDD之前，Temperato先生担任过各种领导职务，包括最著名的Atlantic 医疗保健的美国总裁兼首席运营官，Melinta Therapeutics的总裁兼首席运营官/首席商务官，以及Salix Pharmaceuticals销售和管理市场的高级副总裁。值得注意的是，在Salix Pharmaceuticals Salix，Temperato先生在其广泛的GI投资组合的成功商业化和增长中发挥了关键作用，并在公司任职期间执行了十多次发布，推动公司收入从2004年的1.19亿美元增长到2015年的20亿美元。在整个职业生涯中，Temperato先生一直在定义和执行资本效率高的上市战略，业务发展战略以及监督小分子，设备和生物制剂的商业化和生命周期管理方面发挥重要作用。此外，他还开发了偿还和外部医疗保健政策的策略。他拥有康涅狄格州布里奇波特的布里奇波特大学的理学学士学位。
John Temperato joined our Board in April 2020 upon completion of the RDD Merger and also was appointed our Chief Executive Officer. Mr. Temperato served as the Chief Executive Officer of RDD from March 2019 until April 2020. Prior to joining RDD, Mr. Temperato held various leadership roles, including most notably U.S. President & Chief Operating Officer with Atlantic Healthcare, President & Chief Operating Officer/Chief Commercial Officer with Melinta Therapeutics, and Senior Vice President of Sales and Managed Markets with Salix Pharmaceuticals. Notably, at Salix Pharmaceuticals Salix, Mr. Temperato played a critical role in the successful commercialization and growth of their broad GI portfolio and executed over ten launches during his tenure at the company driving growth of company revenues from $119 million in 2004 to $2 billion in 2015. Across his career, Mr. Temperato has been instrumental in defining and executing capital efficient go-to-market strategies, business development strategy and overseeing the commercialization and life-cycle management for small molecules, devices, and biologics. Additionally, he has developed strategies for reimbursement and external healthcare policy. He holds a Bachelor of Science degree from the University of Bridgeport in Bridgeport, Connecticut. - John Temperato在RDD合并完成后于2020年4月加入我们的董事会，并被任命为我们的首席执行官。Temperato先生从2019年3月至2020年4月担任RDD首席执行官。在加入RDD之前，Temperato先生担任过各种领导职务，包括最著名的Atlantic 医疗保健的美国总裁兼首席运营官，Melinta Therapeutics的总裁兼首席运营官/首席商务官，以及Salix Pharmaceuticals销售和管理市场的高级副总裁。值得注意的是，在Salix Pharmaceuticals Salix，Temperato先生在其广泛的GI投资组合的成功商业化和增长中发挥了关键作用，并在公司任职期间执行了十多次发布，推动公司收入从2004年的1.19亿美元增长到2015年的20亿美元。在整个职业生涯中，Temperato先生一直在定义和执行资本效率高的上市战略，业务发展战略以及监督小分子，设备和生物制剂的商业化和生命周期管理方面发挥重要作用。此外，他还开发了偿还和外部医疗保健政策的策略。他拥有康涅狄格州布里奇波特的布里奇波特大学的理学学士学位。
- John Temperato joined our Board in April 2020 upon completion of the RDD Merger and also was appointed our Chief Executive Officer. Mr. Temperato served as the Chief Executive Officer of RDD from March 2019 until April 2020. Prior to joining RDD, Mr. Temperato held various leadership roles, including most notably U.S. President & Chief Operating Officer with Atlantic Healthcare, President & Chief Operating Officer/Chief Commercial Officer with Melinta Therapeutics, and Senior Vice President of Sales and Managed Markets with Salix Pharmaceuticals. Notably, at Salix Pharmaceuticals Salix, Mr. Temperato played a critical role in the successful commercialization and growth of their broad GI portfolio and executed over ten launches during his tenure at the company driving growth of company revenues from $119 million in 2004 to $2 billion in 2015. Across his career, Mr. Temperato has been instrumental in defining and executing capital efficient go-to-market strategies, business development strategy and overseeing the commercialization and life-cycle management for small molecules, devices, and biologics. Additionally, he has developed strategies for reimbursement and external healthcare policy. He holds a Bachelor of Science degree from the University of Bridgeport in Bridgeport, Connecticut.
高管简历
中英对照 | 中文 | 英文- Edward J. Sitar
Edward J. Sitar，2013年3月加入9 Meters Biopharma, Inc.之前，从2013年1月至2013年12月，Sita先生是Healthagen，一家Aetna公司的首席财务官。在Healthagen之前，2010年8月到2013年1月，Sita先生担任ActiveHealth管理，一家Aetna公司的执行副总裁兼首席财务官。2001年4月到2010年5月，他担任Cadent控股，一家私营，能为牙医和牙齿矫正者提供三维数字扫描服务公司的执行副总裁兼首席财务官。Sita先生1998年8月到2001年4月，担任MIM，现在BioScrip，一家上市专业制药和药物收益管理服务提供商公司的首席财务官和财务总监。1996年5月到1996年8月，Sitar先生是Vital Signs，一家上市专业的医疗产品制造商和经销商的金融副总裁。1993年6月到1996年4月，Sitar先生是Zenith的总会计师。1982年到1993年7月，他在Coopers & Lybrand，一家会计师事务所工作。他拥有斯克兰顿大学会计专业学士学位。
Edward J. Sitar, became 9 Meters Biopharma, Inc. Chief Financial Officer in July 2019. Most recently he served as the Chief Financial Officer of Ammon Analytical Laboratory, a company focused on specialty testing for the drug treatment community, from April 2017 to November 2018. Previously, he served as the Chief Financial Officer of Cancer Genetics, Inc. CGIX, a company focused on precision medicine for oncology, from March 2014 until February 2017. Prior to his service at Cancer Genetics, he served from January 2013 to December 2013 as the Chief Financial Officer-New Business of Healthagen, an Aetna company offering health products and services, and served as Chief Financial Officer of ActiveHealth Management from August 2010 to December 2012. From April 2001 to May 2010 he served as Executive Vice President and Chief Financial Officer of Cadent Holdings, Inc., a privately-held company that provided three-dimensional digital scanning services for dentists and orthodontists. From August 1998 to April 2001 Mr. Sitar served as Chief Financial Officer and Treasurer of MIM Corporation, now BioScrip, Inc., a publicly traded specialty pharmaceutical and pharmacy benefit management service provider. From May 1996 to August 1998 Mr. Sitar was the Vice President of Finance for Vital Signs, Inc., a publicly traded manufacturer and distributor of single use medical products. From June 1993 to April 1996 Mr. Sitar was the Controller of Zenith. From 1982 through July 1993 he was with Coopers & Lybrand, a public accounting firm. He holds a B.S. in accounting from the University of Scranton and is licensed as a Certified Public Accountant in New Jersey.- Edward J. Sitar，2013年3月加入9 Meters Biopharma, Inc.之前，从2013年1月至2013年12月，Sita先生是Healthagen，一家Aetna公司的首席财务官。在Healthagen之前，2010年8月到2013年1月，Sita先生担任ActiveHealth管理，一家Aetna公司的执行副总裁兼首席财务官。2001年4月到2010年5月，他担任Cadent控股，一家私营，能为牙医和牙齿矫正者提供三维数字扫描服务公司的执行副总裁兼首席财务官。Sita先生1998年8月到2001年4月，担任MIM，现在BioScrip，一家上市专业制药和药物收益管理服务提供商公司的首席财务官和财务总监。1996年5月到1996年8月，Sitar先生是Vital Signs，一家上市专业的医疗产品制造商和经销商的金融副总裁。1993年6月到1996年4月，Sitar先生是Zenith的总会计师。1982年到1993年7月，他在Coopers & Lybrand，一家会计师事务所工作。他拥有斯克兰顿大学会计专业学士学位。
- Edward J. Sitar, became 9 Meters Biopharma, Inc. Chief Financial Officer in July 2019. Most recently he served as the Chief Financial Officer of Ammon Analytical Laboratory, a company focused on specialty testing for the drug treatment community, from April 2017 to November 2018. Previously, he served as the Chief Financial Officer of Cancer Genetics, Inc. CGIX, a company focused on precision medicine for oncology, from March 2014 until February 2017. Prior to his service at Cancer Genetics, he served from January 2013 to December 2013 as the Chief Financial Officer-New Business of Healthagen, an Aetna company offering health products and services, and served as Chief Financial Officer of ActiveHealth Management from August 2010 to December 2012. From April 2001 to May 2010 he served as Executive Vice President and Chief Financial Officer of Cadent Holdings, Inc., a privately-held company that provided three-dimensional digital scanning services for dentists and orthodontists. From August 1998 to April 2001 Mr. Sitar served as Chief Financial Officer and Treasurer of MIM Corporation, now BioScrip, Inc., a publicly traded specialty pharmaceutical and pharmacy benefit management service provider. From May 1996 to August 1998 Mr. Sitar was the Vice President of Finance for Vital Signs, Inc., a publicly traded manufacturer and distributor of single use medical products. From June 1993 to April 1996 Mr. Sitar was the Controller of Zenith. From 1982 through July 1993 he was with Coopers & Lybrand, a public accounting firm. He holds a B.S. in accounting from the University of Scranton and is licensed as a Certified Public Accountant in New Jersey.
- John Temperato
John Temperato在RDD合并完成后于2020年4月加入我们的董事会，并被任命为我们的首席执行官。Temperato先生从2019年3月至2020年4月担任RDD首席执行官。在加入RDD之前，Temperato先生担任过各种领导职务，包括最著名的Atlantic 医疗保健的美国总裁兼首席运营官，Melinta Therapeutics的总裁兼首席运营官/首席商务官，以及Salix Pharmaceuticals销售和管理市场的高级副总裁。值得注意的是，在Salix Pharmaceuticals Salix，Temperato先生在其广泛的GI投资组合的成功商业化和增长中发挥了关键作用，并在公司任职期间执行了十多次发布，推动公司收入从2004年的1.19亿美元增长到2015年的20亿美元。在整个职业生涯中，Temperato先生一直在定义和执行资本效率高的上市战略，业务发展战略以及监督小分子，设备和生物制剂的商业化和生命周期管理方面发挥重要作用。此外，他还开发了偿还和外部医疗保健政策的策略。他拥有康涅狄格州布里奇波特的布里奇波特大学的理学学士学位。
John Temperato joined our Board in April 2020 upon completion of the RDD Merger and also was appointed our Chief Executive Officer. Mr. Temperato served as the Chief Executive Officer of RDD from March 2019 until April 2020. Prior to joining RDD, Mr. Temperato held various leadership roles, including most notably U.S. President & Chief Operating Officer with Atlantic Healthcare, President & Chief Operating Officer/Chief Commercial Officer with Melinta Therapeutics, and Senior Vice President of Sales and Managed Markets with Salix Pharmaceuticals. Notably, at Salix Pharmaceuticals Salix, Mr. Temperato played a critical role in the successful commercialization and growth of their broad GI portfolio and executed over ten launches during his tenure at the company driving growth of company revenues from $119 million in 2004 to $2 billion in 2015. Across his career, Mr. Temperato has been instrumental in defining and executing capital efficient go-to-market strategies, business development strategy and overseeing the commercialization and life-cycle management for small molecules, devices, and biologics. Additionally, he has developed strategies for reimbursement and external healthcare policy. He holds a Bachelor of Science degree from the University of Bridgeport in Bridgeport, Connecticut.- John Temperato在RDD合并完成后于2020年4月加入我们的董事会，并被任命为我们的首席执行官。Temperato先生从2019年3月至2020年4月担任RDD首席执行官。在加入RDD之前，Temperato先生担任过各种领导职务，包括最著名的Atlantic 医疗保健的美国总裁兼首席运营官，Melinta Therapeutics的总裁兼首席运营官/首席商务官，以及Salix Pharmaceuticals销售和管理市场的高级副总裁。值得注意的是，在Salix Pharmaceuticals Salix，Temperato先生在其广泛的GI投资组合的成功商业化和增长中发挥了关键作用，并在公司任职期间执行了十多次发布，推动公司收入从2004年的1.19亿美元增长到2015年的20亿美元。在整个职业生涯中，Temperato先生一直在定义和执行资本效率高的上市战略，业务发展战略以及监督小分子，设备和生物制剂的商业化和生命周期管理方面发挥重要作用。此外，他还开发了偿还和外部医疗保健政策的策略。他拥有康涅狄格州布里奇波特的布里奇波特大学的理学学士学位。
- John Temperato joined our Board in April 2020 upon completion of the RDD Merger and also was appointed our Chief Executive Officer. Mr. Temperato served as the Chief Executive Officer of RDD from March 2019 until April 2020. Prior to joining RDD, Mr. Temperato held various leadership roles, including most notably U.S. President & Chief Operating Officer with Atlantic Healthcare, President & Chief Operating Officer/Chief Commercial Officer with Melinta Therapeutics, and Senior Vice President of Sales and Managed Markets with Salix Pharmaceuticals. Notably, at Salix Pharmaceuticals Salix, Mr. Temperato played a critical role in the successful commercialization and growth of their broad GI portfolio and executed over ten launches during his tenure at the company driving growth of company revenues from $119 million in 2004 to $2 billion in 2015. Across his career, Mr. Temperato has been instrumental in defining and executing capital efficient go-to-market strategies, business development strategy and overseeing the commercialization and life-cycle management for small molecules, devices, and biologics. Additionally, he has developed strategies for reimbursement and external healthcare policy. He holds a Bachelor of Science degree from the University of Bridgeport in Bridgeport, Connecticut.